In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...

Without policy intervention to address average sales price-based challenges to biosimilar market sustainability, there is a ...

Prior authorization is a barrier to accessing medications for opioid use disorder (MOUD). Although private insurance covered about one-third of patients with OUD in 2023, the understanding of prior ...

US v. Skrmetti undermined constitutional guardrails that guarantee rigorous assessment of medical justifications for policies limiting the rights of transgender people and women, creating a need and ...

Ryan N. Hansen, PharmD, PhD, is professor and chair of the Department of Pharmacy, and faculty in the CHOICE Institute, School of Pharmacy, University of Washington, and chief technology officer at ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of ...

While recent fertility drug-related announcements by the Trump administration could result in savings for women—especially ...

The No Surprises Act has protected patients from surprise medical bills. However, the law’s incentives for insurers acting as ...

It is essential to weigh the report’s recommendations not only for their technical merit but also for their political ...

The North Carolina State Health Plan experience shows us that large, self-insured employers can work to bend the cost curve ...

For now, the most reasonable stance is watchful waiting: acknowledging the real problems WISeR seeks to address, recognizing ...